

Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

I, Francois Houyez

Organisation/Company: N/A

Country: Netherlands

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

1.1 Employment

No interest declared

1.2 Consultancy

No interest declared

1.3 Strategic advisory role

No interest declared

1.4 Financial interests

No interest declared

1.5 Principal investigator

No interest declared

1.6 Investigator

No interest declared

1.7 Grant / Funding to organisation /institution

Name of pharmaceutical company	Subject Matter
Bayer AG,BioCryst Pharmaceuticals, INC.,Lundbeck A/S,Novo Nordisk HQ,Takeda Pharmaceuticals Internat	Eurordis Round Table of Companies RESTRI
Adelphi,Charles River Microbial Solutions Germany GmbH,Charles River Microbial Solutions Germany Gmb	UNSOLICITED 2023
Alexion, AstraZeneca Rare Disease, Alnylam Switzerland GmbH, Amylyx Pharmaceuticals EMEA B.V.,Biogen	Black Pearl 2023
Aeglea Biotherapeutics,Alexion - AstraZeneca Rare Disease,Alnylam Switzerland GmbH,Amicus Therapeuti	Eurordis Round Table of Companies UNREST
Bristol Myers Squibb (BMS),Chiesi,Horizon Therapeutics,NOVARTIS FARMA S.p.A.,PTC Therapeutics,Record	EURORDIS International Initiatives 2023
CSL BEHRING,NOVARTIS FARMA S.p.A.,Roche,Swedish Orphan Biovitrum BVBA,	PROJECT DEVELOPMENT 2023

Alexion - AstraZeneca Rare Disease,Biogen (Czech Republic) s.r.o,Chiesi,Clinigen Ltd,CSL BEHRING,Hor	Eurordis membership Meeting 2023
Amicus Therapeutics UK Ltd,BIOMARIN,Bristol Myers Squibb (BMS),CSL BEHRING,JANSSEN - a J&J company,S	RARE BAROMETER 2023

1.8 Close family member interest

No interest declared

1.9 Repurposing of a medicinal product

Time Period	Start Date	End Date	Product Name	Therapeutic indication	Involvement in the repurposing
Current	01-09-2022		losartan	osteogenesis imperfecta	non-active-champion
Current	01-09-2022		crizotinib	COVID-19	non-active-champion
Current	01-09-2022		rimcazole	COVID-19	non-active-champion
Current	01-09-2022		simvastatin	pancreatic cancer	non-active-champion
Current	01-09-2022		tazarotene	multiple sulfatase deficiency	non-active-champion
Current	01-09-2022		valproic acid	pancreatic cancer	non-active-champion

1.10 Any other interests or facts

Other colleagues provide consultancy advice to pharmaceutical companies and I am not directly involved in the provision of such advice. I am not systematically informed about this interaction, I do not know when it happens, with which companies and for which agenda, so I cannot list the interactions.

Member of the Ethics and scientific Advisory Board, Vaccelerate project (VACCCELERATE _ The European Vaccine Accelerator Platform.)

Member of the Get Real Institute and Executive Board

1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation /institution

Name of pharmaceutical company	Subject Matter
Illumina, GRIFOLS S.A.	Eurordis Round Table of companies uNREST

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

Other colleagues provide consultancy advice to pharmaceutical companies and I am not directly involved in the provision of such advice. I am not systematically informed about this interaction, I do not know when it happens, with which companies and for which agenda, so I cannot list the interactions.

Member of the Ethics and scientific Advisory Board, Vaccelerate project (VACCCELERATE _ The European Vaccine Accelerator Platform.)
Member of the Get Real Institute and Executive Board

There are other companies producing medical devices funding my organisation but i don't have all details as of 13 June 2023 when I filled-in this declaration.

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together

with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name:	Francois Houyez
Date:	2023-06-13

For definitions of activities etc, refer to the policy on handling of competing interests.